首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1548159

全球肝癌診斷市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Liver Cancer Diagnostic Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球肝癌診斷市場需求預計將從2023年的938909萬美元達到2032年近1825896萬美元的市場規模，2024-2032年研究期間複合年成長率為7.67%。

肝癌診斷是指用於檢測和確認肝癌（也稱為肝細胞癌）存在的方法和程序。此診斷過程通常涉及影像技術的組合，包括電腦斷層掃描 (CT)、超音波和磁振造影 (MRI)，以可視化腫瘤並評估其範圍。血液檢查，包括肝功能檢查和甲胎蛋白 (AFP) 等生物標記物，有助於評估肝臟健康狀況和癌症的存在。準確的診斷通常需要進行活體組織切片，即透過顯微鏡檢查組織樣本中的癌細胞。及時、準確的診斷對於有效治療和更好的結果至關重要。

市場動態

由於全球肝癌盛行率不斷上升，肝癌診斷市場正在經歷成長。乙型和丙型肝炎感染率上升、飲酒量增加和肥胖等因素導致肝癌發病率不斷上升，從而導致對有效診斷解決方案的需求增加。早期檢測可以提高治療效果，從而推動對先進診斷技術的需求。技術進步為市場帶來了重大機會。影像技術的創新，例如高解析度 MRI 和先進的超音波技術，可以提供更準確、更詳細的肝臟腫瘤可視化。此外，開發非侵入性診斷測試（例如液體活體組織切片和分子生物標記）為傳統活體組織切片方法提供了一個有希望的替代方案，提高了患者的舒適度和診斷準確性。

腫瘤學中對個人化醫療的日益重視為肝癌診斷創造了更多機會。遺傳和基因組測試的進步可以識別特定的腫瘤特徵和突變，從而實現量身定做的治療方法並改善患者管理。這一趨勢支持了對提供全面分子和遺傳資訊的先進診斷工具的需求。擴大新興市場的醫療保健基礎設施和增加醫療保健投資有助於市場成長。隨著這些地區發展醫療保健系統並增加獲得診斷技術的機會，對肝癌診斷的需求預計將會上升。此外，有關肝癌及其危險因素的認知和教育計劃的興起增強了早期發現工作。促進篩檢和早期診斷的公共衛生措施透過增加診斷測試的採用來進一步支持市場成長。然而，與先進診斷技術相關的高成本以及服務欠缺地區獲得醫療保健的機會有限可能會抑制市場成長。

這項詳細的市場研究以從多個來源獲得的資料為中心，並使用多種工具進行分析，包括波特五力分析、市場吸引力分析和價值鏈分析。這些工具用於深入了解市場的潛在價值，為業務策略家提供最新的成長機會。此外，這些工具還提供了全球肝癌診斷市場中每個應用/產品細分的詳細分析。

市場區隔

廣泛的肝癌診斷市場已細分為測試類型和最終用戶。該報告根據地理細分研究了這些子集。策略師可以獲得詳細的洞察並針對特定市場制定適當的策略。這些細節將導致採取有針對性的方法，從而識別更好的機會。

按測試類型

實驗室檢驗（生物標記、血液檢驗）
影像學
內視鏡檢查
活體組織切片
其他

按最終用途

醫院和診斷實驗室
學術及研究機構
製藥和 CRO 實驗室
區域分析
此外，該報告還進行了地理細分，主要關注北美、歐洲、亞太地區、拉丁美洲以及中東和非洲地區肝癌診斷的當前和預測需求。該報告進一步關注所有地區對各個應用領域的需求。
該報告還涵蓋了詳細的競爭格局，包括在全球市場上營運的主要參與者的公司簡介。肝癌診斷市場的主要參與者包括 Abbott Laboratories、F. Hoffmann-La Roche Ltd.、Qiagen NV、Thermo Fisher Scientific Inc.、Siemens Healthineers、Becton Dickinson & Company、Illumina Inc.、Koninklijke Philips NV、Epigenomics AG、 Fujifilm Medical Inc. Systems USA Inc. 深入了解競爭前景，包括未來產能、關鍵併購、財務概覽、合作夥伴關係、合作、新產品發布、新產品開發和其他發展，並提供總部資訊

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：肝癌診斷公司的競爭格局

肝癌診斷市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Abbott Laboratories

公司概況
公司收入
產品
最新動態

F. Hoffmann-La Roche Ltd.

公司概況
公司收入
產品
最新動態

Qiagen NV

公司概況
公司收入
產品
最新動態

Thermo Fisher Scientific Inc.

公司概況
公司收入
產品
最新動態

Siemens Healthineers

公司概況
公司收入
產品
最新動態

Becton Dickinson & Company

公司概況
公司收入
產品
最新動態

Illumina Inc.

公司概況
公司收入
產品
最新動態

Koninklijke Philips NV

公司概況
公司收入
產品
最新動態

Epigenomics AG

公司概況
公司收入
產品
最新動態

Fujifilm Medical Systems USA Inc.

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11210557

The global demand for Liver Cancer Diagnostic Market is presumed to reach the market size of nearly USD 18258.96 Million by 2032 from USD 9389.09 Million in 2023 with a CAGR of 7.67% under the study period 2024 - 2032..

Liver cancer diagnostic refers to the methods and procedures used to detect & confirm the presence of liver cancer, also known as hepatocellular carcinoma. This diagnostic process typically involves a combination of imaging techniques, including computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI), to visualize tumors and assess their extent. Blood tests, including liver function tests and biomarkers like alpha-fetoprotein (AFP), help evaluate liver health and cancer presence. An accurate diagnosis frequently necessitates a biopsy, where a tissue sample is examined microscopically for cancer cells. Timely & precise diagnosis is integral for effective treatment & better outcomes.

Market Dynamics

The liver cancer diagnostic market is experiencing growth fuelled by the rising prevalence of liver cancer worldwide. Factors such as rising rates of hepatitis B & C infections, increasing alcohol consumption, and obesity contribute to the growing incidence of liver cancer, leading to heightened demand for effective diagnostic solutions. Early detection enhances treatment outcomes, thereby driving the need for advanced diagnostic technologies. Technological advancements present significant opportunities in the market. Innovations in imaging techniques, such as high-resolution MRI and advanced ultrasound technologies, provide more accurate and detailed visualization of liver tumors. Additionally, developing non-invasive diagnostic tests, such as liquid biopsies and molecular biomarkers, offers promising alternatives to traditional biopsy methods, improving patient comfort and diagnostic accuracy.

The growing emphasis on personalized medicine in oncology creates further opportunities for liver cancer diagnostics. Genetic and genomic testing advances allow for identifying specific tumor profiles and mutations, enabling tailored treatment approaches and improving patient management. This trend supports the demand for advanced diagnostic tools that provide comprehensive molecular and genetic information. Expanding healthcare infrastructure and increasing healthcare investments in emerging markets contribute to market growth. As these regions develop their healthcare systems and increase access to diagnostic technologies, the demand for liver cancer diagnostics is expected to rise. Moreover, the rise of awareness and education programs regarding liver cancer and its risk factors enhances early detection efforts. Public health initiatives that promote screening and early diagnosis further support market growth by increasing the adoption of diagnostic tests. However, high costs associated with advanced diagnostic technologies and limited access to healthcare in underserved regions can restrain market growth.

This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of liver cancer diagnostic.

Market Segmentation

The broad liver cancer diagnostic market has been sub-grouped into test type and end-user. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Test Type

Laboratory Tests (Biomarkers, Blood Tests)
Imaging
Endoscopy
Biopsy
Others

By End-use

Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Pharmaceutical & CRO Laboratories
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for liver cancer diagnostic in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the Liver Cancer Diagnostic market includes Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips N.V, Epigenomics AG, Fujifilm Medical Systems U.S.A. Inc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LIVER CANCER DIAGNOSTIC - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Test Type
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY TEST TYPE

5.1. Overview By Test Type
5.2. Historical and Forecast Data
5.3. Analysis By Test Type
5.4. Laboratory Tests (Biomarkers, Blood Tests) Historic and Forecast Sales By Regions
5.5. Imaging Historic and Forecast Sales By Regions
5.6. Endoscopy Historic and Forecast Sales By Regions
5.7. Biopsy Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY END-USE

6.1. Overview By End-use
6.2. Historical and Forecast Data
6.3. Analysis By End-use
6.4. Hospitals & Diagnostic Laboratories Historic and Forecast Sales By Regions
6.5. Academic & Research Institutes Historic and Forecast Sales By Regions
6.6. Pharmaceutical & CRO Laboratories Historic and Forecast Sales By Regions

7. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE LIVER CANCER DIAGNOSTIC COMPANIES

8.1. Liver Cancer Diagnostic Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF LIVER CANCER DIAGNOSTIC INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abbott Laboratories
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. F. Hoffmann-La Roche Ltd.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Qiagen N.V.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Thermo Fisher Scientific Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Siemens Healthineers
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Becton Dickinson & Company
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Illumina Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Koninklijke Philips N.V
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Epigenomics AG
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Fujifilm Medical Systems U.S.A. Inc.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments